# A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

> **NCT07221838** · PHASE4 · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis
- gMG

## Interventions

- **PROCEDURE:** Oral Corticosteroid Tapering Schedule
- **DRUG:** Ravulizumab
- **DRUG:** Prednisone/Prednisolone

## Key facts

- **NCT ID:** NCT07221838
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2027-08-27
- **Final completion:** 2027-08-27
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221838, "A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07221838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*